2026 Q3 - tulosraportti
3 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 26 990 | ||
| 13 010 | ||
| 200 | ||
| 1 079 | ||
| 18 721 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 25.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 5.11. | ||
2026 Q2 - tulosraportti 21.8. | ||
2026 Q1 - tulosraportti 29.4. | ||
2025 Q4 - tulosraportti 26.2. | ||
2025 Q3 - tulosraportti 25.11.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·11 t sitten · MuokattuI have already stopped pretending that Ani has a high enough market cap to actually have anything to do with the bidding war for this TAM 60-120 B SEK drug! Ani is pulling out all the stops and making a bid corresponding to 25-30% of their own market cap, but it is still a lowball bid that barely corresponds to 1/12 of what Egetis is worth. The youngsters on Egetis board of directors seem mostly interested in cashing out before they go Christmas shopping.
·19 t sittenWarrenAI: "11,25 kr offers too little for the remaining commercial potential. A rational counter-offer according to this risk-adjusted negotiation framework is around 12,50–13,00 kr" I would personally like to see the bid around 14,50-15,00 kr for the premium to satisfy me reasonably. But to be satisfied with the current bid, wait for a new bid or in the last case to take the risk that Egetis continues its journey - there we have the question🤔
Understand well why management recommends with that portion of warrants • The total scope: The company states in its financial reports that full exercise of the outstanding incentive programs (employee options and certain lender warrants) will increase the number of shares by up to 36.279.164 pcs.- ·21 t sittenThere are still great hopes for a bidding war in my opinion. Acceptance period for the bid has not yet started and it runs until December 18, 2026. There are major shareholders who have not yet taken a position. Major shareholders who have not accepted the bid: Feoh Investments voting rights (6.05 %) - recently bought up AP4's shares in a block. Handelsbanken Fonder (approx. 5.4%). Linc AB (3.9%), Has during the year bought shares for around 51 million and signals via CEO that they see that the market generally for acquisitions is in a positive phase with many players who have money to put into acquisitions. AP4 has 3.64% left of the shares in its portfolio. In total this gives around 19%. Considering that Linc has tanked Egetis shares throughout the year and that Feoh bought a block directly from AP4's holding recently it feels like they have a handle on the market and want to get more of the value out in Egetis. There is not much discussion about buyers also getting RTH-beta and Aladote which can develop all at once. Since none of the 4 major owners signal that they intend to commit to ANI's bid, definitely neither will I. They are waiting (as far as I currently know) and they hopefully know more than we do. Nice weekend, you will have to excuse spelling and formatting - sitting in a car writing on phone 😎
·2 päivää sitten · MuokattuANIP also released its Q3 report yesterday Nov 5 where the acquisition of Egetis was given major space. Available to read or listen to. They appear to be a good match for Egetis. The problem is "only" a too low bid. Hope someone else steps in.I personally will not accept the offer, think it must be min over 35 - if you look at the risk we have taken in the development phase up to the FDA approval ! Could be interesting what management will get in bonus if the deal is executed!
·2 päivää sittenI bought 🤣
If it becomes 90% yes, and the bid then goes through. How does this happen in practice?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q3 - tulosraportti
3 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·11 t sitten · MuokattuI have already stopped pretending that Ani has a high enough market cap to actually have anything to do with the bidding war for this TAM 60-120 B SEK drug! Ani is pulling out all the stops and making a bid corresponding to 25-30% of their own market cap, but it is still a lowball bid that barely corresponds to 1/12 of what Egetis is worth. The youngsters on Egetis board of directors seem mostly interested in cashing out before they go Christmas shopping.
- ·19 t sittenWarrenAI: "11,25 kr offers too little for the remaining commercial potential. A rational counter-offer according to this risk-adjusted negotiation framework is around 12,50–13,00 kr" I would personally like to see the bid around 14,50-15,00 kr for the premium to satisfy me reasonably. But to be satisfied with the current bid, wait for a new bid or in the last case to take the risk that Egetis continues its journey - there we have the question🤔Understand well why management recommends with that portion of warrants • The total scope: The company states in its financial reports that full exercise of the outstanding incentive programs (employee options and certain lender warrants) will increase the number of shares by up to 36.279.164 pcs.
- ·21 t sittenThere are still great hopes for a bidding war in my opinion. Acceptance period for the bid has not yet started and it runs until December 18, 2026. There are major shareholders who have not yet taken a position. Major shareholders who have not accepted the bid: Feoh Investments voting rights (6.05 %) - recently bought up AP4's shares in a block. Handelsbanken Fonder (approx. 5.4%). Linc AB (3.9%), Has during the year bought shares for around 51 million and signals via CEO that they see that the market generally for acquisitions is in a positive phase with many players who have money to put into acquisitions. AP4 has 3.64% left of the shares in its portfolio. In total this gives around 19%. Considering that Linc has tanked Egetis shares throughout the year and that Feoh bought a block directly from AP4's holding recently it feels like they have a handle on the market and want to get more of the value out in Egetis. There is not much discussion about buyers also getting RTH-beta and Aladote which can develop all at once. Since none of the 4 major owners signal that they intend to commit to ANI's bid, definitely neither will I. They are waiting (as far as I currently know) and they hopefully know more than we do. Nice weekend, you will have to excuse spelling and formatting - sitting in a car writing on phone 😎
- ·2 päivää sitten · MuokattuANIP also released its Q3 report yesterday Nov 5 where the acquisition of Egetis was given major space. Available to read or listen to. They appear to be a good match for Egetis. The problem is "only" a too low bid. Hope someone else steps in.I personally will not accept the offer, think it must be min over 35 - if you look at the risk we have taken in the development phase up to the FDA approval ! Could be interesting what management will get in bonus if the deal is executed!
- ·2 päivää sittenI bought 🤣If it becomes 90% yes, and the bid then goes through. How does this happen in practice?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 26 990 | ||
| 13 010 | ||
| 200 | ||
| 1 079 | ||
| 18 721 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 25.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 5.11. | ||
2026 Q2 - tulosraportti 21.8. | ||
2026 Q1 - tulosraportti 29.4. | ||
2025 Q4 - tulosraportti 26.2. | ||
2025 Q3 - tulosraportti 25.11.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q3 - tulosraportti
3 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 25.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 5.11. | ||
2026 Q2 - tulosraportti 21.8. | ||
2026 Q1 - tulosraportti 29.4. | ||
2025 Q4 - tulosraportti 26.2. | ||
2025 Q3 - tulosraportti 25.11.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·11 t sitten · MuokattuI have already stopped pretending that Ani has a high enough market cap to actually have anything to do with the bidding war for this TAM 60-120 B SEK drug! Ani is pulling out all the stops and making a bid corresponding to 25-30% of their own market cap, but it is still a lowball bid that barely corresponds to 1/12 of what Egetis is worth. The youngsters on Egetis board of directors seem mostly interested in cashing out before they go Christmas shopping.
- ·19 t sittenWarrenAI: "11,25 kr offers too little for the remaining commercial potential. A rational counter-offer according to this risk-adjusted negotiation framework is around 12,50–13,00 kr" I would personally like to see the bid around 14,50-15,00 kr for the premium to satisfy me reasonably. But to be satisfied with the current bid, wait for a new bid or in the last case to take the risk that Egetis continues its journey - there we have the question🤔Understand well why management recommends with that portion of warrants • The total scope: The company states in its financial reports that full exercise of the outstanding incentive programs (employee options and certain lender warrants) will increase the number of shares by up to 36.279.164 pcs.
- ·21 t sittenThere are still great hopes for a bidding war in my opinion. Acceptance period for the bid has not yet started and it runs until December 18, 2026. There are major shareholders who have not yet taken a position. Major shareholders who have not accepted the bid: Feoh Investments voting rights (6.05 %) - recently bought up AP4's shares in a block. Handelsbanken Fonder (approx. 5.4%). Linc AB (3.9%), Has during the year bought shares for around 51 million and signals via CEO that they see that the market generally for acquisitions is in a positive phase with many players who have money to put into acquisitions. AP4 has 3.64% left of the shares in its portfolio. In total this gives around 19%. Considering that Linc has tanked Egetis shares throughout the year and that Feoh bought a block directly from AP4's holding recently it feels like they have a handle on the market and want to get more of the value out in Egetis. There is not much discussion about buyers also getting RTH-beta and Aladote which can develop all at once. Since none of the 4 major owners signal that they intend to commit to ANI's bid, definitely neither will I. They are waiting (as far as I currently know) and they hopefully know more than we do. Nice weekend, you will have to excuse spelling and formatting - sitting in a car writing on phone 😎
- ·2 päivää sitten · MuokattuANIP also released its Q3 report yesterday Nov 5 where the acquisition of Egetis was given major space. Available to read or listen to. They appear to be a good match for Egetis. The problem is "only" a too low bid. Hope someone else steps in.I personally will not accept the offer, think it must be min over 35 - if you look at the risk we have taken in the development phase up to the FDA approval ! Could be interesting what management will get in bonus if the deal is executed!
- ·2 päivää sittenI bought 🤣If it becomes 90% yes, and the bid then goes through. How does this happen in practice?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 26 990 | ||
| 13 010 | ||
| 200 | ||
| 1 079 | ||
| 18 721 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt